Acticor Biotech SAS
PAR: ALACT.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gilles Avenard
- Employees
- 31
- Headquarters
- Paris, France
- IPO year
- 2021
- Market cap
- €3.9M
- Website
- https://acticor-biotech.com
Loading ALACT…
Loading profile data…Frequently asked questions about ALACT
What does Acticor Biotech SAS (ALACT.PA) do?
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for...
Where does ALACT.PA trade?
Acticor Biotech SAS (ALACT.PA) trades on the Euronext Paris.
What sector is ALACT.PA in?
Acticor Biotech SAS (ALACT.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Acticor Biotech SAS?
Gilles Avenard is the chief executive officer of Acticor Biotech SAS (ALACT.PA).
Where is Acticor Biotech SAS headquartered?
Acticor Biotech SAS is headquartered in France.
Does ALACT.PA pay a dividend?
Acticor Biotech SAS (ALACT.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALACT.PA go public?
Acticor Biotech SAS (ALACT.PA) completed its initial public offering in 2021.